title: Characterization of the Antiglioma Effect of the Oncolytic Adenovirus VCN-01.
abstract: Despite the recent advances in the development of antitumor therapies, the prognosis for patients with malignant gliomas remains dismal. Therapy with tumor-selective viruses is emerging as a treatment option for this devastating disease. In this study we characterize the anti-glioma effect of VCN-01, an improved hyaluronidase-armed pRB-pathway-selective oncolytic adenovirus that has proven safe and effective in the treatment of several solid tumors. VCN-01 displayed a significant cytotoxic effect on glioma cells in vitro. In vivo, in two different orthotopic glioma models, a single intra-tumoral administration of VCN-01 increased overall survival significantly and led to long-term survivors free of disease.
authors.affiliation: Navarra's Health Research Institute (IDISNA) Pamplona, Spain.|Program in Solid Tumors and Biomarkers, Foundation for the Applied Medical Research, Pamplona, Spain.|Dpt of Medical Oncology, University Hospital of Navarra, Pamplona 31008, Spain.
authors.forename: Beatriz
authors.initials: B
authors.lastname: Vera
authors.affiliation: Navarra's Health Research Institute (IDISNA) Pamplona, Spain.|Program in Solid Tumors and Biomarkers, Foundation for the Applied Medical Research, Pamplona, Spain.|Dpt of Medical Oncology, University Hospital of Navarra, Pamplona 31008, Spain.
authors.forename: Naiara
authors.initials: N
authors.lastname: Martínez-Vélez
authors.affiliation: Navarra's Health Research Institute (IDISNA) Pamplona, Spain.|Program in Solid Tumors and Biomarkers, Foundation for the Applied Medical Research, Pamplona, Spain.|Dpt of Medical Oncology, University Hospital of Navarra, Pamplona 31008, Spain.
authors.forename: Enric
authors.initials: E
authors.lastname: Xipell
authors.affiliation: Navarra's Health Research Institute (IDISNA) Pamplona, Spain.|Program in Solid Tumors and Biomarkers, Foundation for the Applied Medical Research, Pamplona, Spain.|Dpt of Medical Oncology, University Hospital of Navarra, Pamplona 31008, Spain.
authors.forename: Arlet
authors.initials: A
authors.lastname: Acanda de la Rocha
authors.affiliation: Navarra's Health Research Institute (IDISNA) Pamplona, Spain.|Dpt of Pediatrics, University Hospital of Navarra, Pamplona 31008, Spain.
authors.forename: Ana
authors.initials: A
authors.lastname: Patiño-García
authors.affiliation: Navarra's Health Research Institute (IDISNA) Pamplona, Spain.|Brain Tumor Biology Unit, University of Navarra School of Sciences, 31008 Pamplona, Spain.
authors.forename: Javier
authors.initials: J
authors.lastname: Saez-Castresana
authors.affiliation: Navarra's Health Research Institute (IDISNA) Pamplona, Spain.|Program in Solid Tumors and Biomarkers, Foundation for the Applied Medical Research, Pamplona, Spain.|Dpt of Medical Oncology, University Hospital of Navarra, Pamplona 31008, Spain.
authors.forename: Marisol
authors.initials: M
authors.lastname: Gonzalez-Huarriz
authors.affiliation: VCN Biosciences, Sant Cugat del Vallés, 08174 Barcelona, Spain.
authors.forename: Manel
authors.initials: M
authors.lastname: Cascallo
authors.affiliation: Translational Research Laboratory, IDIBELL-Institut Catalá d'Oncologia, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
authors.forename: Ramón
authors.initials: R
authors.lastname: Alemany
authors.affiliation: Navarra's Health Research Institute (IDISNA) Pamplona, Spain.|Program in Solid Tumors and Biomarkers, Foundation for the Applied Medical Research, Pamplona, Spain.|Dpt of Medical Oncology, University Hospital of Navarra, Pamplona 31008, Spain.
authors.forename: Marta M
authors.initials: MM
authors.lastname: Alonso
mesh_terms: D017500:Adenovirus E1A Proteins / Q000235:genetics; D000260:Adenoviruses, Human / Q000235:genetics / Q000502:physiology*; D000818:Animals; D001932:Brain Neoplasms / Q000473:pathology / Q000628:therapy*; D045744:Cell Line, Tumor; D003588:Cytopathogenic Effect, Viral; D050687:E2F1 Transcription Factor / Q000235:genetics; D005813:Genes, Synthetic; D005814:Genes, Viral; D005910:Glioma / Q000473:pathology / Q000628:therapy*; D006801:Humans; D006821:Hyaluronoglucosaminidase / Q000235:genetics; D015552:Injections, Intralesional; D051379:Mice; D014411:Neoplastic Stem Cells; D009842:Oligopeptides / Q000235:genetics; D050130:Oncolytic Virotherapy; D050504:Oncolytic Viruses / Q000235:genetics / Q000502:physiology*; D030781:Organisms, Genetically Modified; D014779:Virus Replication; D023041:Xenograft Model Antitumor Assays
chemical_list: D017500:Adenovirus E1A Proteins; C084301:E1A protein 243R, Human adenovirus type 5; D050687:E2F1 Transcription Factor; C493753:E2F1 protein, human; D009842:Oligopeptides; C047981:arginyl-glycyl-aspartic acid; D006821:Hyaluronoglucosaminidase